Scientific Research News

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the Phase III registrational trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 (Mesutoclax) in combination with BTK inhibitor orelabrutinib as a first-line therapy for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China. The fixed-dur...

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, highlights activity at recent scientific conferences and announces participation in future events. Highlights include: March 12, 2025 – Presented at the Society for Immunotherapy of Cancer Spring Scientific Meeting titled, “Novel GITR Agonist KROS 101: A Dual Approach to Boost T Cell Immunity and Alter the Tumor Microenvironment” March 17 to 19 – Participated in the BIO Europe co...

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided an update on its portfolio of AI-driven drug candidates, the RADR® platform for precision oncology drug...

DENVER--(BUSINESS WIRE)--Cleerly, the leader in cardiovascular AI imaging, announces its participation in the American College of Cardiology Annual Scientific Session + Expo (ACC.25) from March 29-31, 2025, at the McCormick Place Convention Center in Chicago, Illinois. Cleerly will share its late-breaking findings on Artificial Intelligence-based Quantitative Computed Tomography’s (AI-QCT’s) role in identifying risks of future major adverse cardiovascular events (MACE) in women. Onsite, Cleerly...

SAN DIEGO--(BUSINESS WIRE)--Physicians and affiliated researchers from Ivy Fertility, a globally-recognized network of fertility centers, shared cutting-edge research at the 73rd Annual Meeting of the Pacific Coast Reproductive Society (PCRS) in Indian Wells, California last week. “Ivy Fertility is proud to provide the world’s most compassionate fertility care, and that commitment is supported by our investment in industry-leading science,” said Ivy Fertility CEO Lisa Van Dolah. “By continually...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first data presentation from the pivotal 3475A-D77 Phase 3 trial, evaluating the subcutaneous administration of pembrolizumab, together with berahyaluronidase alfa (MK-3475A; from now on referred to as “subcutaneous pembrolizumab”). Berahyaluronidase alfa is a variant of human hyaluronidase developed and manufactured by Alteogen Inc. These results are being presented today...

EL SEGUNDO, Calif.--(BUSINESS WIRE)--Lightship Inc., a leading provider of community-based, decentralized clinical trial services, is pleased to announce the appointment of Michael Shipton as Chief Commercial Officer (CCO). With a proven track record of driving growth and innovation in the life sciences and technology sectors, Shipton will play a key role in reshaping Lightship’s go-to-market strategy and strengthening its ability to meet the growing complexity of representative clinical trials...

PALO ALTO, Calif.--(BUSINESS WIRE)--Archetype AI—the Physical AI company helping humanity make sense of the world—today introduced Lenses, a new category of AI application designed to solve complex challenges in the physical world. Lenses are built with Archetype's Newton™ foundation model and allow businesses, from consumer electronics to construction and manufacturing, to easily transform objective sensor data into customized, actionable insights. Archetype pioneered the Physical AI category...

SYDNEY--(BUSINESS WIRE)--Novotech, a top global clinical trial provider, partners with biotech and pharma to speed siRNA therapeutic development....

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2024 annual results as of 31 December 2024. Financial Highlights Revenue of Orelabrutinib increased by 49.1% to RMB 1,000.4 million1 in 2024, mainly driven by rapid growth of marginal zone lymphoma (MZL) indication and strong commercial execution. Total revenue increased by 36.7% to RMB 1,009.4 million in 2024. Gross Profit inc...